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1. Introduction  
The main objective of aortic valve replacement (AVR) is to relieve left ventricular (LV) 
burden and normalized LV mass (LVM). During AVR, many surgeons make final decision 
to select the size of the prosthetic valve based on intraoperative measurement. It is ideal to 
place an aortic prosthesis that is appropriately sized to the patient. However, this is not 
always possible owing to insufficient aortic annular dimensions. Patients receive a 
prosthesis that is too small in relation to their body size have persistent abnormally high 
gradients across the valve and may even show deterioration of symptoms and 
hemodynamics after AVR. Rahimtoola first described the concept of patient-prosthesis 
mismatch (PPM), which was defined as existing “when the effective prosthetic valve area, 
after insertion into the patient, is less than that of a normal valve” 1. The optimal 
prosthetic valve should have several characteristics, including a sufficiently large effective 
orifice area (EOA) with a reduced transvalvular pressure gradient around zero, long-term 
durability, and anticoagulability. There is no optimal, commercially available prosthesis. 
The normal aortic valve has 3.0-4.5 cm2 of EOA, but this is rarely achieved with present 
commercially available prostheses, which means that the result of AVR may be 
suboptimal in many patients. In general, PPM is considered to be present when an 
indexed EOA (IEOA) adjusted for body surface area (BSA) is <0.85 cm2/m2 2-4. Although, 
many studies have shown that PPM adversely affects survival and postoperative cardiac 
function 2-4, many studies contradict these findings 5-12. Thus, there is considerable 
controversy regarding the effects of PPM on survival and postoperative recovery of 
cardiac functions. Patients with a small aortic annulus is still challenging and usually 
require several surgical measures to minimize the PPM, such as use of supra-annular 
implantation technique, high-performance prostheses, aortic annular enlargement, or the 
Ross procedure. The surgical strategy is determined based on the individual patient’s 
conditions, including the size of the aortic annulus, patient’s age, BSA, preoperative 
activity level, and ventricular function. Avoiding the risk of severe PPM defined as an 
IEOA <0.70 cm2/m2, which may prevent symptom resolution and regression of left 
ventricular hypertrophy and may adversely affect late cardiac events and survival, must 
always be considered by taking appropriate surgical strategies, but, it is more important 
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to consider whether the benefits of avoiding PPM overcome the drawbacks of other 
complicated measures in each individual patient. 
2. General consideration 
2.1 Left ventricular-aortic pressure gradients 
Gradients are minimal after AVR with aortic and pulmonary autograft or allograft but are 
present after mechanical or bioprosthetic AVR in virtually all patients. Their magnitude 
varies greatly, determined primarily by the characteristics of the prosthesis itself, the size 
of the prosthesis relative to the size of the patient, and the cardiac output (whether the 
study was done during rest or exercise). Smaller-sized stented bioprostheses and 
mechanical prostheses can result with residual transvalvular gradients. In clinical, 
conventional mechanical prostheses and bioprostheses larger than the 21-mm size can 
provide satisfactory performance in most adults. On the other hand, the small resting 
gradients associated with conventional 19-mm prostheses may become 30 to 50 mmHg 
during periods of increased cardiac output. However, in patients with small body size, 
when the patient’s body surface area is less than 1.5 m2, (with their smaller cardiac 
output) conventional 19-mm devices may perform satisfactorily. The relationship between 
peak left ventricular-aortic gradient and prosthesis size was mainly dependent on the 
patient’s BSA. 
3. Definitions of PPM 
In general, PPM is considered to be present when an IEOA is <0.85 cm2/m2 2-4. IEOA has 
been reported as an index that correlates with the severity of PPM 2-6. In present chapter, 
mild to moderate PPM is defined as when an IEOA of ≥0.70cm2/m2 and <0.85 cm2/m2, and 
severe PPM is defined as when an IEOA of less than 0.69 cm2/m2.  
3.1 Effect of PPM on valve related event and survival 
Blais et al. reported the results of 2981 patients who underwent AVR with a stented 
bioprosthesis 3. According to the literature, patients with an EOAI <0.75 cm2/m2 was a 
significant risk factor for increased operative mortality and valve related deaths during 
the follow-up period. Medalion et al. reported the long-term results of 892 patients who 
underwent AVR 7. Moderate PPM had no influence on survival, but advanced age, 
chronic obstructive pulmonary disease, chronic renal failure, and smoking were 
significant risk factors. Urso et al. showed improvement in postoperative NHYA class 
and regression of LVMI during long-term follow-up in patients who underwent AVR 
with a 19-mm mechanical valve 12. We also showed that PPM with an EOAI ≥0.75 
cm2/m2 but <0.85 cm2/m2 has no effect on operative, short-term, and long-term survival 
and the effect of PPM with an IEOA <0.75 cm2/m2 on survival appeared to decrease over 
time 11. Surviving patients with an IEOA <0.75 cm2/m2 showed good long-term survival. 
Although, the effect of PPM on postoperative valve related event and late survival could 
not be definitively determined due to lack of a radomised large population and long-
term follow-up study, in some patients with mild to moderate PPM could be tolerable in 
patients with preserved LV function without any impact on overall survival.  
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3.2 The significance of IEOA 
Recently, aortic valve stenosis has become the leading type of valvular heart disease in 
developed countries, and such stenosis is no longer caused by rheumatic fever but is due 
to aging. Consequently, the age of candidates for AVR have increased markedly and 
have more risk factors and complications. These findings suggest that surgery becomes 
more complicated. Moreover, most patients with aortic stenosis have calcific aortic valve 
sclerosis, which typically becomes clinically significant in seventh or eighth decade of 
life. Therefore, the incidence of patients with a small aortic annulus with calcification is 
also increasing, especially in Japan. This may result in increasing number of patients 
with PPM after AVR. Some previous studies have reported that the risk factors for AVR 
patients with aortic stenosis developing PPM postoperatively are female gender and 
advanced age 2-4, 10. Aortic annular enlargement procedures should achieve the optimal 
measurements to prevent PPM, but these procedures lengthen the cardiopulmonary 
bypass and cross clamp times, increasing the surgical risks. Several reports demonstrated 
that aortic annular enlargement is related to increased operative mortality 15. In such 
circumstance, surgery should be restricted to the minimum necessary. The EOA of 
commercially available prosthetic valves was only 49 - 66% that of a normal aortic valve 
1-9. PPM patients have significantly higher persistent pressure gradients across the valve 
prosthesis than patients without significant PPM. It is well recognized that the 
transvalvular pressure gradient increases exponentially with a decrease in prosthetic 
valve EOA 4. A small decrease in EOA results in a relatively large increase in the 
transvalvular pressure gradient. Several reports demonstrated that PPM increases LV 
workload due to the residual pressure gradient, which prevents regression of LVM and 
increases operative mortality and valve-related events 1-6. The definition of the threshold 
degree of severe PPM that must be avoided due to an adverse effect on survival is 
important. Tasca et al. reported that there was a positive correlation between LVM and 
IEOA, and patients with an IEOA <0.80 cm2/m2 showed inadequate regression of LVM 
after AVR. Moreover, an inadequate regression of LVM positively affected the rate of 
valve-related events after AVR and patients with an IEOA <0.70 cm2/m2 showed 
regression of indexed LVM; LVMI (LVM adjusted for BSA), but LVMI increased again 
during the follow-up period 6. This phenomenon suggests that AVR contributes to 
decreasing the pressure gradient across the valve to less than that of the preoperative 
state. Decreased workload to the left ventricle can lead to regression of LVMI in the 
postoperative acute phase. However, LV workload remains high after AVR due to 
persistent PPM, which may increase LVM again during the follow-up period. On the 
other hand, many studies have been reported that mild to moderate PPM appears to 
have little or no effect on postoperative recovery of cardiac function, late cardiac events 
and survival5-12. Such degree of PPM may be acceptable in not only elderly patients but 
also younger patients7. We also reported that the postoperative peak pressure gradient 
across the prosthesis was significantly higher in patients with PPM than in patients 
without PPM, but postoperative cardiac function, including LV function, LVMI, and 
NYHA class, improved in all patients despite having PPM; the degree of improvement in 
cardiac function in patients with PPM compared favorably to that in patients without 
PPM 11. Avoiding the risk of severe PPM, must always be considered, but, it is more 
important to consider whether the benefits of avoiding PPM overcome the drawbacks of 
other complicated measures in each individual patient. There is controversy about 
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applying a unified standard for avoiding PPM to every patients requiring AVR 
regardless of their age and preoperative condition. The current perception of PPM based 
on the value of IEOA may need to be reconsidered for select populations. Based on these 
findings, IEOA ranges from 0.70 cm2/m2 to 0.75 cm2/m2 may be a lower tolerable 
threshold limit 5-11.  
3.3 Optimal surgery for patients with advanced age 
In general, elderly patients have decreased physiological reserve, and unexpected 
bleeding could occur during the operation due to tissue fragility, which may result in 
difficulty achieving hemostasis. In such circumstances, surgery should be restricted to 
the minimum necessary to obtain improved performance. Elderly patients with a short 
stature, in a relatively inactive, if the patient’s LV function remains preserved, then it is 
not necessary to replace the valve with a larger prosthesis to ensure an IEOA ≥0.85 
cm2/m2, or even to perform additional aortic root enlargement. PPM with an IEOA <0.85 
cm2/m2 and ≥0.70 cm2/m2 could be tolerable without any impact on overall survival5-11.  
4. Introduction of high-performance prostheses 
4.1 Prosthetic performance 
In contrast to other risk factors, PPM can be largely avoided with the use of a prospective 
strategy at the time of operation. Determine patient’s BSA and estimate the minimum 
required prosthetic size for patient. Confirm the indicated sizer pass through the patient’s 
aortic annulus. Currently, high-performance mechanical or bioprosthetic valves that have a 
larger EOA than those of corresponding labeled sizes of conventional prostheses have been 
introduced 13, 14. These valves have a low incidence of PPM without performing annular 
enlargement, especially in the small valve sizes. In recent years, patients who require AVR 
are becoming older and thus have more risk factors and complications. In such 
circumstances, operative invasiveness should be minimized, and there is a tendency to 
perform isolated AVR with a high-performance prosthesis instead of performing aortic 
annular enlargement. However, there are several drawbacks and advantages in high-
performance prostheses. Stentless prosthesis can avoid PPM with excellent hemodynamics, 
but implantation of this prosthesis is more complicated than that of standard AVR. SJM 
Regent valve has a larger EOA than the corresponding same-labeled size of SJM standard 
valve. On the other hand, the thickness of the external sewing ring of SJM Regent valve is 
very thin, so that considerable concern might exist about the fit between the external sewing 
ring and the native aortic annulus. Making an appropriate choice with regard to the 
prosthesis is important. 
Table 1 shows currently available several types of high-performance mechanical prostheses, 
which includes the conventional type of St. Jude Medical Standard aortic valve (Medtronic, 
Minneapolis, MN, USA) for comparison; St. Jude Medical Hemodynamic Plus; St. Jude 
Medical Regent; and ATS AP 360 (ATS Medical Inc, Minneapolis, MN, USA). For each type 
and size of prosthetic valve, the estimates of the prostheses’ EOAs were obtained from the 
manufacturers’ instructions.  
The spectrum of biological valve substitutes for the small aortic annulus includes stented 
and stentless porcine valves, stented pericardial valves, aortic or pulmonary homografts, 
and pulmonary autografts. Table 2 shows currently available several types of high-
www.intechopen.com
 Operative Management – Patient-Prosthesis Mismatch 
 
89 
performance bioprostheses, which includes the conventional type of Carpentier-Edwards 
Perimount aortic valve (Edwards Lifesciences, Irvine, CA, USA) for comparison; Carpentier-
Edwards Perimount Magna; Mosaic Porcine Bioprosthesis (Medtronic, Minneapolis, MN, 
USA); and Freestyle Aortic Root Bioprosthesis (Medtronic). For each type and size of 




Size (mm) 16 17 18 19 20 21 22 23 25 
SJM Standard 1.00 1.30 1.60 1.80 
SJM HP 1.00 1.30 1.60 
SJM Regent 1.30 1.70 2.00 2.50 2.60 
ATS AP360 1.20 1.50 1.70 2.10 
Results are the effective orifice area (cm2) 
SJM, St. Jude Medical; HP, Hemodynamic Plus; 
ATS, ATS Medical      
Table 1. Effective orifice area of each high-performance mechanical prosthesis 
 
Prosthesis 
Size (mm) 19 21 23 25 27 29 
CEP 1.28 1.69 1.87 1.89 
CEP Magna 1.58 1.90 2.07 2.33 
Mosaic 1.20 1.30 1.50 1.80 2.00 2.10 
Freestyle-s 1.10 1.40 1.60 2.00 2.40 2.70 
Freestyle-f 1.20 1.40 1.70 2.10 2.40 2.70 
Results are the effective orifice area (cm2) 
CEP, Carpentier-Edwards Perimount 
Freestyle-s, Freestyle subcoronary 
Freestyle-f, Freestyle full root 
Table 2. Effective orifice area of each high-performance bioprosthesis 
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5. Surgery for small aortic annulus 
Ideally, a patient with a small aortic annulus should be identified preoperatively, so that 
alternative measures, such as an aortic root-enlarging procedure or a selection of high-
performance prosthesis, might be considered. Occasionally, the precise size of the aortic 
annulus cannot be determined until the time of operation. 
5.1 Supra-annular implantation 
One-size up prosthesis implantation can be allowed using supra-annular position or single 
suture technique. Other approach to the slightly smaller aortic annulus is to implant 
prosthesis at a slight angle to the plane of the annulus 16. After the sutures are placed in the 
annulus for a supra-annular position, they are passed through the sewing ring and lowered 
into place so that the sewing ring is below the left and right coronary arteries but angled 
upward at the noncoronary sinus. The left and right annulus sutures are tied first, thereby 
securing the sewing ring to the annulus below the left and right coronary ostia. The sutures 
that correspond to the noncoronary annulus are tied last, allowing the valve to ride slightly 
above the annulus in this region.  
5.2 Aortic root enlargement  
Annular enlargement procedures are alternatives for those patients in whom a prosthesis 
being implanted is too small in relation to body size (at least 19-mm cannot be implanted). 
Although, Manouguian’s or the Nicks procedure for annular enlargement may increase 
operative risks, these procedures can allow larger prosthesis implantation in patients with 
small aortic annulus 15. Among surviving patients, aortic annular enlargement improved 
long-term outcome. Recently, with the introduction of high-performance prostheses and 
changes in the patient’s age group, the need for aortic annular enlargement has decreased 
dramatically in our clinical practice.  
5.3 Nicks procedure 
Nicks et al. reported a technique for the enlargement of a small aortic root by an operation 
whereby the small aortic root has been enlarged by insertion of a Dacron fabric gusset that 
it will accommodate a larger sized prosthesis 17. In many cases, enlarging the annulus by 
2-4 mm may be sufficient. One technique associated with minimal increase in morbidity is 
to create a posterior annular split at noncoronary cusps, leaving the anterior mitral leaflet 
and the left atrium intact. The aortic incision is carried downwards posteriorly through 
the noncoronary aortic sinus across the aortic annulus as far as the origin of the mitral 
valve, just above the confluence of the intervalvular trigone, left atrial wall, and mitral 
annulus. A tongue of Dacron fabric is sutured down to the fibrous origin of the mitral 
annulus.  
5.4 Manoughian procedure 
Manoughian et al. reported when greater annular enlargement is desired, a posterior 
incision is made at the commissure between the left and noncoronary cusp and extended 
through the annulus and the intervalvular trigone into the center of the anterior mitral 
leaflet 18. The free edge and body of the anterior leaflet remain intact. The left atrium, which 
is entered at its attachment with the aortic root, can be opened further to facilitate exposure. 
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An elliptical patch is used to close the defect in the anterior mitral leaflet. Interrupted 
horizontal mattress sutures are placed in the annulus and also through the patch. The 
prosthesis is thus seated, using the patch as part of the annulus. The incision in the left atrial 
wall is closed by continuous sutures by incorporating the atrial edges as the patch is sutured 
to the defect in the anterior mitral leaflet. The superior portion of the patch is incorporated 
into the aortotomy closure. Mitral regurgitation due to distortion of the anterior mitral 
leaflet may occur. 
5.5 Konno procedure 
Patients with congenital aortic stenosis have associated hypoplasia of the aortic annulus. In 
such cases, valvotomy is of limited value, and standard AVR is unfeasible because of the 
narrow aortic root. In such cases, Konno procedure is indicated 19. The procedure consists of 
a longitudinal incision in the aortic septum placed in the midportion of the two coronary 
ostia, a vertical incision in the outflow tract of the right ventricle to join the septal incision, 
AVR with prosthetic valve, and patch reconstruction of the outflow tracts of both ventricles 
by means of two layers of a fusiform Dacron patch.  
5.6 Stentless bioprosthesis 
The stentless porcine bioprosthesis has become increasingly popular, because stentless 
xenograft valves have several advantages over the traditional stent mounted tissue 
valves. Notably, stented xenograft valves are intrinsically obstructive due to the space 
occupied by the stent and sewing ring. For a given external diameter, the internal 
diameter of the stentless valve is 2 to 4 mm larger than a stent mounted xenograft valve 
due to lack of a stent. This translates to an ability to place a bioprosthesis with a greater 
EOA, reduce mean transvalvular gradients, and results in greater regression of LV 
hypertrophy compared to the stented bioprosthesis. An increased understanding of the 
functional anatomy of the aortic root has reinforced the concept of the dynamic 
relationships among the valve cusps, annulus, sinus of Valsalva, and sinotubular 
junction. The use of a stentless valve maintains these interactions resulting in improved 
hemodynamic performance. Stentless valves can be implanted in the subcoronary 
position, as an aortic root replacement, or as a root inclusion. Although, subcoronary 
implantation, aortic root replacement, and root inclusion are similar to techniques, 
implantation of a stentless xenograft aortic valve is technically more difficult than a 
stented valve but easier than an allograft used in the subcoronary position. Two valves 
approved for use by the United States Food and Drug Administration are the Toronto 
SPV (St. Jude, Minneapolis, MN) and the Freestyle valve (Medtronic, Minneapolis, MN). 
The Toronto SPV is comprised of the valve and supporting aortic wall only, and is 
designed as a subcoronary implant. 
5.7 Apicoaortic bypass 
Surgical relief of LV outflow tract obstruction may be difficult to achieve by conventional 
methods. Creation of a LV “vent” was accomplished by the anastomosis of a valved 
conduit graft from LV apex to the abdominal aorta 20. A median sternotomy incision is 
made and extended into the linear alba after the decision is made to insert the conduit. 
The supraceliac aorta is exposed and clamped while the anastomosis is performed. 
During temporary cardiopulmonary bypass a plug of myocardium is removed from the 
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apex of the left ventricle. The rigid inlet tube attached to a sewing ring and fabric graft is 
sutured to the ventricular ostium. The graft passed into the abdomen through  
an incision in the diaphragm and the composite conduit is anastomosed end to end 
fashion.  
5.8 Ross procedure 
The Ross Procedure is a type of specialized aortic valve surgery where the patient's diseased 
aortic valve is replaced with his or her own pulmonary valve 21. The pulmonary valve is 
then replaced with cryopreserved pulmonary allograft. In children and young adults, or 
older particularly active patients, this procedure offers several advantages over traditional 
aortic valve replacement with manufactured prostheses. Longevity of the pulmonary 
autograft in the aortic position is superior to bioprostheses such as porcine valves, which 
tend to degenerate after only a few years in patients under 35 years of age. Furthermore, 
anticoagulation is not required as with mechanical valves. Thus, individuals can lead an 
active life without the risks associated with anticoagulation therapy. This is especially 
important for women of child bearing age needing aortic valve replacement, as 
anticoagulation is contraindicated in pregnancy. However, lifelong follow-up for 
pulmonary autograft, implanted allograft, and the ascending aortic diameter must be 
required. 
6. Conclusions 
PPM with an IEOA <0.70 cm2/m2 should always be avoided. This degree of PPM adversely 
affects operative mortality and postoperative recovery of cardiac functions. However, in 
some cases, PPM with an IEOA <0.85 cm2/m2 and ≥0.70 cm2/m2 could be acceptable in 
patients with preserved LV function without any impact on overall survival. The current 
perception of PPM may need to be reconsidered with respect to the unified standard 
regardless of each patient’s condition. On the other hand, introduction of high-performance 
prostheses reduces the incidence of PPM without performing annular enlargement, 
especially in the small valve sizes. Making an appropriate choice, including the surgical 
strategy and the prosthesis, based on each individual patient’s preoperative condition is 
very important.  
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